{"brief_title": "A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients", "brief_summary": "This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.", "condition": ["Anemia"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["Epoetin alfa or beta", "RO0503821 (1x/2 Weeks)", "RO0503821 (1x/4 Weeks)"], "description": ["intravenously 3 times weekly for 52 weeks, as prescribed", "60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.", "120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks."], "arm_group_label": ["Epoetin (1-3x/Weeks)", "RO0503821 (1x/2 Weeks)", "RO0503821 (1x/4 Weeks)"], "other_name": ["Epoetin", "Mircera", "Mircera"], "criteria": "Inclusion Criteria: - adult patients >=18 years of age; - chronic renal anemia; - on dialysis therapy for at least 12 weeks before screening; - receiving IV epoetin for at least 8 weeks before screening. Exclusion Criteria: - women who are pregnant, breastfeeding or using unreliable birth control methods; - administration of another investigational drug within 4 weeks before screening, or during the study period.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Anemia", "Epoetin Alfa"], "id": "NCT00077610"}